secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001654954-24-003868
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set
-------------------------------------------------------------------

- Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.
- Full year 2023 net loss $10.1M ($1.58/share) vs $13.2M ($4.56) in 2022.
- Cash and cash equivalents $2.8M as of December 31, 2023.
- Installed first TAEUS system at King's College Hospital UK for 75-subject clinical study.
- FDA De Novo review ongoing; in-person meeting scheduled for Q2 2024 after Additional Information request.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-003868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer